GENE ONLINE|News &
Opinion
Blog

2021-11-16| In-DepthSpecial

How is China Driving Global Progress in Innovation and Access? – A Discussion with BeiGene CEO John Oyler

by Rajaneesh K. Gopinath
Share To
In the past few years, including the pandemic hit 2020, a record number of partnerships were signed between global pharma groups and Chinese startups, signifying how far the country has opened up its healthcare market.

In a CEO interview session at the Financial Times Global Pharmaceutical and Biotechnology Conference, Sarah Neville, FT's Global Health Editor, discussed with John V. Oyler, Founder, and CEO of BeiGene about how China successfully expands its pharma capabilities beyond manufacturing into innovation and market access.

John described China as a dynamic participant in the global drug discovery and development field. He mentioned that the changes in the last decade happened as a result of government policies and regulatory reforms that encouraged innovations and China's active participation in the global system.

It's free! Log in now to read

LATEST
Vaccine Protecting Against 20 Different Pneumococcal Infections Proves Effective in Trial
2022-08-12
FDA Approves Roche’s Established Antiviral For Children Aged Five Or Older
2022-08-12
Novartis Reported Two Deaths Following Zolgensma Gene Therapy
2022-08-12
Extreme Climate Change Is Aggravating Infectious Diseases!
2022-08-11
In Response to Expanding Monkeypox Outbreak, FDA Approves Emergency Use of JYNNEOS Vaccine
2022-08-11
Potential $1 billion Acquisition of TeneoTwo by AstraZeneca comes to Fruition
2022-08-11
Gene Repair Therapy: First Patient Dosed With New Treatment for Sickle Cell Disease
2022-08-11
EVENT
2022-09-09
ESMO 2022 Exhibition
Online and on-side
2022-09-20
Cell & Gene Therapy USA 2022
Virtual
2022-09-21
CSCO Educational Book 2022
Xiamen
2022-09-21
RESI Boston
Boston
2022-09-26
Human Gene Therapy Conference
Australia
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!